The aim of Taina Mattila’s research is to highlight some of the current challenges in schizophrenia research and to demonstrate how analyses on raw study data from drug registration trials can answer a variety of related research questions and aid decision-making in regulatory and clinical practice. She uses individual patient data from 22 double-blind, randomised and placebo-controlled studies into the effect and safety of treatment for patients with schizophrenia.
T.K. Mattila: Bridging from Drug Registration Trials to Meaningful Clinical Evidence – The Case of Schizophrenia.
Prof. D.A.J.P. Denys
Prof. H.G.M. Leufkens (University of Utrecht)
Dr T.D. Wohlfarth (College ter Beoordeling Geneesmiddelen)
Dr M.W.J. Koeter
This event is open to the public.